Incidence of Respiratory Syncytial Virus in Community-Dwelling Adults Aged 18-64 Years Over 2 Seasons, 2022-2024, in a North American Community.
Wendelyn Bosch, Lisa J Speiser, Chung-Il Wi, Katherine S King, Traci L Natoli, Kathy D Ihrke, Matthew J Spiten, Matthew J Binnicker, Joseph D Yao, Paul Y Takahashi, Robert J Pignolo, Brandon H Hidaka, Randy M Foss, Jean-Yves Pir��on, Pouya Saeedi, Mohamed Oujaa, Young J Juhn
Author Information
Wendelyn Bosch: Division of Infectious Diseases, Mayo Clinic, Jacksonville, Florida, USA. ORCID
Lisa J Speiser: Division of Infectious Diseases, Mayo Clinic, Phoenix, Arizona, USA. ORCID
Chung-Il Wi: Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA. ORCID
Katherine S King: Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA. ORCID
Traci L Natoli: Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Kathy D Ihrke: Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Matthew J Spiten: Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Matthew J Binnicker: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Joseph D Yao: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. ORCID
Paul Y Takahashi: Division of Community Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. ORCID
Robert J Pignolo: Divisions of Hospital Internal Medicine, Endocrinology, and Geriatric Medicine and Gerontology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Brandon H Hidaka: Northwest Wisconsin Family Medicine, Mayo Clinic Health System, Wisconsin, USA. ORCID
Randy M Foss: Southeast Minnesota Family Medicine, Mayo Clinic Health System, Minnesota, USA. ORCID
Young J Juhn: Department of Pediatric and Adolescent Medicine and Internal Medicine, Mayo Clinic and Mayo Clinic Health System, Rochester, Minnesota, USA. ORCID
Background: The incidence of respiratory syncytial virus (RSV)-acute respiratory infection (ARI) in community-dwelling adults after the Omicron variant of the COVID-19 pandemic is unknown. Our aim was to assess the incidence of RSV-ARI in adults aged 18 to 64 years over 2 consecutive RSV seasons (October-April 2022-2024) in 4���US states. Methods: This community-based prospective cohort study comprised 7501 participants in Minnesota, Wisconsin, Florida, and Arizona. We calculated RSV-ARI and RSV-lower respiratory tract disease (LRTD) incidence and attack rates. We reported unadjusted incidence by age group, gender, race and ethnicity, Charlson Comorbidity Index, socioeconomic status, residential state, and rural/urban setting. Results: Seasons 1 and 2 had 2250 and 2377 ARI episodes, respectively, with an RSV-ARI positivity rate of 5.5% for season 1 and 5.8% for season 2 among those tested. In season 1, the overall incidence of RSV-ARI was 27.71 (95% CI, 22.82-33.34) per 1000 person-years (1.49% attack rate). Almost half (49.0%) had RSV-LRTD, with an incidence of 13.53 (95% CI, 10.19-17.61) per 1000 person-years (0.73% attack rate). In season 2, the RSV-ARI and RSV-LRTD incidence rates were 26.39 (95% CI, 21.73-31.75) per 1000 person-years (1.51% attack rate) and 12.43 (95% CI, 9.31-16.26) per 1000 person-years (0.72% attack rate). RSV-ARI incidence peaked in November 2022 and December 2023. Conclusions: Our observations suggest that RSV-ARI incidence and seasonal pattern are shifting to prepandemic RSV epidemiology.
